Jad Chahoud/moffitt.org
Aug 22, 2025, 11:59
Jad Chahoud Shares an Article About a New Phase 2 Trial on First-Line Treatment for Advanced NSCLC
Jad Chahoud, Genitourinary Medical Oncologist at Moffitt Cancer Center, shared an article by Shaodong Hong et al. published in Nature Medicine on X:
”Phase 2 OptiTROP-Lung01 Sacituzumab tirumotecan (ADC) + anti–PD-L1in 1L advanced NSCLC (no driver mutations):
- ORR: 40% (q3w) vs 67% (q2w)
- DCR: 85–92%
- mPFS: 15.4 mo (q3w), NR (q2w)”
Title: First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial
Authors: Shaodong Hong, Qiming Wang, Ying Cheng, Yongzhong Luo, Xiujuan Qu, Haibo Zhu, Zhenyu Ding, Xingya Li, Lin Wu, Yan Wang, Sheng Hu, Enwen Wang, Anwen Liu, Yuping Sun, Yun Fan, Feng Ye, Kaihua Lu, Jian Fang, Yuping Shen, Xiaoping Jin, Junyou Ge, Li Zhang, Wenfeng Fang
You can read the Full Article here.
More posts featuring Jad Chahoud.
Anwen Liu
cancer
Enwen Wang
Feng Ye
Haibo Zhu
Immunotherpy
Jad Chahoud
Jian Fang
Junyou Ge
Kaihua Lu
Li Zhang
Lin Wu
Lung cancer
Nature Medicine
OncoDaily
Oncology
Qiming Wang
Shaodong Hong
Sheng Hu
Wenfeng Fang
Xiaoping Jin
Xingya Li
Xiujuan Qu
Yan Wang
Ying Cheng
Yongzhong Luo
Yun Fan
Yuping Shen
Yuping Sun
Zhenyu Ding
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 22, 2025, 11:57
Aug 22, 2025, 11:54
Aug 22, 2025, 11:44
Aug 22, 2025, 11:36
Aug 22, 2025, 11:25
Aug 22, 2025, 11:06
Aug 22, 2025, 10:50